Cargando…

Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management

Multiple myeloma (MM) is associated with increased risk of infection, but little is known regarding antibody levels against specific bacteria. We assessed levels of polyclonal immunoglobulin and antibacterial antibodies in patients recruited to the TEAMM trial, a randomised trial of antibiotic proph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chicca, Ilaria J., Heaney, Jennifer L. J., Iqbal, Gulnaz, Dunn, Janet A., Bowcock, Stella, Pratt, Guy, Yong, Kwee L., Planche, Timothy D., Richter, Alex, Drayson, Mark T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642409/ https://www.ncbi.nlm.nih.gov/pubmed/33149136 http://dx.doi.org/10.1038/s41408-020-00370-7

Ejemplares similares

Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial
por: Bowcock, Stella, et al.
Publicado: (2023)

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
por: Drayson, Mark T, et al.
Publicado: (2019)

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials
por: Heaney, Jennifer L. J., et al.
Publicado: (2018)

Use of patient diaries in conjunction with standard reporting methods: duplication of data or a valuable resource?
por: Dunn, Janet, et al.
Publicado: (2015)

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
por: Ramasamy, Karthik, et al.
Publicado: (2022)

Investigating the utility of saliva immunoglobulins for the detection of myeloma and using myeloma proteins to clarify partition between oral and systemic immunity
por: Heaney, Jennifer L. J., et al.
Publicado: (2022)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs
por: Kolovos, Spyros, et al.
Publicado: (2019)

Systematic review of interventions to increase recruitment and retention of black, minority and ethnic patients into randomised controlled trials
por: Iqbal, Gulnaz, et al.
Publicado: (2013)

Under-representation of male patients in breast cancer studies
por: Mistry, Pankaj, et al.
Publicado: (2015)

Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test
por: Heaney, Jennifer L. J., et al.
Publicado: (2017)

Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report
por: Rana, Ritika, et al.
Publicado: (2021)

VAD chemotherapy as remission induction for multiple myeloma.
por: Anderson, H., et al.
Publicado: (1995)

Active multiple myeloma suppresses and typically eliminates coexisting MGUS
por: Campbell, John P, et al.
Publicado: (2017)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
por: Cook, Gordon, et al.
Publicado: (2019)

Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient
por: Innao, Vanessa, et al.
Publicado: (2017)

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial
por: Royle, Kara-Louise, et al.
Publicado: (2022)

Dissecting racial disparities in multiple myeloma—clues from differential immunoglobulin levels
por: Bunce, C. M., et al.
Publicado: (2020)

Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial
por: Santosa, Damai, et al.
Publicado: (2022)

The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2019)

Secondary CNS myeloma with remission after systemic CNS-penetrating agents
por: Fernandez, Luis G, et al.
Publicado: (2022)

UK ethnicity data collection for healthcare statistics: the South Asian perspective
por: Iqbal, Gulnaz, et al.
Publicado: (2012)

Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
por: Bird, Sarah, et al.
Publicado: (2021)

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
por: Coulson, Amy Beth, et al.
Publicado: (2022)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
por: Shah, Vallari, et al.
Publicado: (2020)

Ultrasound remission in patients with rheumatoid arthritis in clinical remission
por: Fakhfakh, Rym, et al.
Publicado: (2021)

The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
por: Striha, Alina, et al.
Publicado: (2018)

Myeloma patients’ experiences of a supervised physical activity programme: a qualitative study
por: Land, Joanne, et al.
Publicado: (2022)

Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial
por: Pawlyn, Charlotte, et al.
Publicado: (2020)

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure
por: Hutchison, Colin A, et al.
Publicado: (2008)

PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma
por: McCourt, Orla, et al.
Publicado: (2020)

Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma
por: Ahmedzai, Sam H., et al.
Publicado: (2019)

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma
por: Yadav, Punit, et al.
Publicado: (2018)

Astrocytoma development following complete multiple myeloma remission in a 49-year-old patient: A case report
por: HAN, XIAOYAN, et al.
Publicado: (2013)

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
por: Steinhardt, Maximilian Johannes, et al.
Publicado: (2020)

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial
por: Jones, John R., et al.
Publicado: (2023)

Hypoattenuating periportal halo on CT in a patient population can occur in presence of a variety of diseases
por: Dressel-Böhm, Susann, et al.
Publicado: (2022)

Bacterial Taxa and Functions Are Predictive of Sustained Remission Following Exclusive Enteral Nutrition in Pediatric Crohn’s Disease
por: Jones, Casey M A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3isrmrbskn881d0dhl3uffud0l